Forum Alert: BioMS Medical Corp. will Present at the Informed Investors Biotechnology & Healthcare Investor Forum at The Hyatt Regency in San Francisco on Wednesday, December 7, 2005, 12:50 pm PST
Edmonton, AB - November 28, 2005 /CCN Matthews/ -- BioMS Medical Corp. (TSX: MS) will present at the following forum:
What: Informed Investors Biotechnology & Healthcare Investor Forum in San Francisco
When: December 7, 2005 @ 12:50 PM Pacific Standard Time
Sponsors: Barron’s, The Wall Street Journal and Business Wire
Keynote Presentations: John McCamant, Editor of The Medical Technology Stock Letter
Adam Noah, Ph.D., Vice President, Biotechnology Equity Research,
Merriman Curhan Ford & Co.
Forum Highlights Include: Networking session and Industry Panel Discussion at the
conclusion of the presentations
Where: The Hyatt Regency Hotel, 5 Embarcadero Center, San Francisco, CA 94111
How to attend: Pre-registration is necessary. To register, contact Cary Loeser, cloeser@wilink.com, or 804-327-3407. You may also call Customer Service at 888-301-6618, or register at the following link: http://www.investorcalendar.com/IIF/CustomEvent/90563/index.asp
If you are unable to attend the live event, the forum will be archived and available via webcast at http://www.investorcalendar.com/IIF/CustomEvent/90563/index.asp
Contact: Amanda Stadel, Investor Relations Manager, astadel@biomsmedical.com , (780)413-7152
This press release may contain forward-looking statements, which reflect the Corporation’s current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Corporation’s ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that dirucotide (MBP8298) will continue to demonstrate a satisfactory safety profile in ongoing and future clinical trials; and that BioMS Medical Corp. will complete the respective clinical trials within the timelines communicated in this release. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
| Ryan Giese VP Corporate Communications Phone: 780-413-7152 rgiese@biomsmedical.com |
Tony Hesby Executive VP Corporate Affairs Phone: 780-413-7152 thesby@biomsmedical.com |
Amanda Stadel Investor Relations Manager Phone: 780-413-7152 astadel@biomsmedical.com |